PubMed İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/8
Browse
2 results
Search Results
Article Prevalence of Fecal Incontinence After Childbirth in Turkey: Systematic Review and Meta-Analysis(Springer London Ltd, 2025) Kaya, Husniye Dinc; Gunaydin, Sevil; Kilic, Melek; Ozdemir, Iclal IlknurBackgroundFecal incontinence (FI), defined as the reduced or lost ability to control the elimination of solid or liquid stool and gas due to anal sphincter dysfunction, is mostly caused by childbirth.AimThis study aimed to determine the prevalence of postpartum fecal incontinence in Turkey.MethodsThis systematic review and meta-analysis were conducted between December 1 and December 31, 2024, considering inclusion and exclusion criteria. The literature search was performed using PubMed, Science Direct, Medline, Ovid, Ebsco CINAHL Plus, and Cochrane Library databases. The methodological quality of the included studies was assessed using the checklist developed by the Joanna Briggs Institute.ResultsA total of six studies were included in this review. The combined results indicated that the prevalence of postpartum fecal incontinence in Turkey is approximately 3%. Women who delivered by cesarean section had significantly lower rates of FI than those who delivered vaginally (z = 3.10, p = 0.002, CI: 0.39 [0.21, 0.71]). Additionally, the combined results of the studies showed no significant relationship between fecal incontinence and menopausal status, indicating that premenopausal and postmenopausal women had similar rates of fecal incontinence (z = 0.02, p = 0.98, CI: 0.97 [0.10, 9.47]).ConclusionFecal incontinence can occur after childbirth. The postpartum fecal incontinence rate in Turkey is 3%, and it is associated with the mode of delivery but not with menopausal status. A thorough postpartum examination is recommended for the early detection of fecal incontinence.PROSPERO Registration No: CRD420250653603.ConclusionFecal incontinence can occur after childbirth. The postpartum fecal incontinence rate in Turkey is 3%, and it is associated with the mode of delivery but not with menopausal status. A thorough postpartum examination is recommended for the early detection of fecal incontinence.PROSPERO Registration No: CRD420250653603.Article Citation - WoS: 3Citation - Scopus: 2Hepatitis B Immunization Data of Patients Living With Hiv/Aids: a Multi-Centre Study(Natl inst Public Health, 2022) Ozturk, Servet; Ozel, Ayse Serra; Ergen, Pinar; Senbayrak, Seniha; Agalar, CananObjectives: Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are the two leading viruses that cause the greatest number of virus-related morbidities in the world. HIV/HBV coinfection is correlated with high morbidity and mortality. For this particular reason hepatitis B vaccination is crucial for people living with HIV. Methods: Patients who are being followed-up for HIV/AIDS and who have received a hepatitis B vaccine in 4 HIV clinics over a 5-year time period have been studied. Our multi-centered, retrospective, cross-sectional and observational study investigates factors that affect hepatitis B vaccination immune response of individuals living with HIV. The patients have been studied for the parameters such as age, sex, CD4 count at the time of diagnosis or vaccination, HIV-RNA levels, comorbidities, vaccine dosage, success of immunization after vaccination, and the demographics of the patients who have and have not developed immunity. Results: Of 645 patients that are being followed-up in our clinics, 158 received hepatitis B vaccine; 39 of these 158 patients have been excluded from the study because they did not fulfil the inclusion criteria. Finally, 119 patients were evaluated in the study, 17 of the patients (14.3%) were females and 102 (85.7%) were males. The median age was 41.11 +/- 10.09 (min-max: 18-75). Twenty-three of the patients (19.3%) were at the stage of AIDS during diagnosis while 80.7% were at the stage of HIV infection. Ninety-one of the patients (76.5%) have been administered a single dose hepatitis B vaccine on the standard 0, 1st, 6th month vaccination schedule, whereas 23.5% were administered a double dose on the same vaccination schedule. When further evaluated to find whether the patient was able to develop sufficient immunity (anti-HBs >= 10), it was found that the immune response was statistically significantly higher in the patients whose CD4 count was greater than 200 at the time of the first diagnosis and vaccination (p = 0.05 and p = 0.001, respectively). The patients have also been evaluated according to the number of doses they received (1 vs. 2). The immune response of the patients who received two doses was statistically significantly higher (p = 0.041). Conclusion: We can conclude that in the patients with CD4 count less than 200 at the time of their diagnosis and vaccination a high dose recombinant hepatitis B vaccine should definitely be administered as the normal dose and higher dose have similar side effect profiles and the higher dose provides greater immunity.